Drugs /

bi 1361849

Back to Drugs List

Overview

NCI Definition [1]:
A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine CV9202 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.

Clinical Trials

View Clinical Trials for bi 1361849

Bi 1361849 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating bi 1361849, 1 is phase 1/phase 2 (1 open).

Non-small cell lung carcinoma is the most common disease being investigated in bi 1361849 clinical trials [2].

Drug Details

Synonyms [2]:
mrna-derived lung cancer vaccine cv9202, cv9202, mrna-derived lung cancer vaccine bi 1361849, bi1361849
NCIT ID [1]:
C111574

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.